CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 592 enrolled
Drug / intervention
Maridebart Cafraglutide +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05669599
NCT05669599Phase 2Completed
CompareCT.gov

A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Amgen·interventional·Posted Jan 3, 2023·Updated Jan 20, 2026

In Brief

A Phase 2 clinical trial evaluating Maridebart Cafraglutide and Placebo for Obesity and 2 related conditions. Completed, enrolled 592 participants across 78 sites in 12 countries.

Detailed Summary

The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or obesity without diabetes mellitus (Cohort A) and in participants with overweight or obesity with Type 2 diabetes mellitus (Cohort B).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Overweight, Type 2 Diabetes Mellitus
CountriesAustralia, Canada, Czechia, Germany, Hong Kong, Hungary, Japan, Poland, South Korea, Spain, Taiwan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedJan 3, 2023
Enrollment StartJan 18, 2023
Primary CompletionOct 8, 2024
Study CompletionDec 16, 2025
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 3.5 years ago

Interventions

Maridebart Cafraglutidebiological

Participants will receive maridebart cafraglutide by subcutaneous (SC) injection.

Placebodrug

Participants will receive placebo by SC injection.